MedTrace Logo

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

NCT01966003 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2017-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.

Conditions

  • Non-small Cell Lung Cancer Metastatic

Interventions

DRUG

Carboplatin

Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W

DRUG

Paclitaxel

Administered 200 mg/m² IV Q3W

DRUG

ABP 215

Administered 15 mg/kg Q3W by IV infusion

DRUG

Bevacizumab

Administered 15 mg/kg Q3W by IV infusion

Sponsors & Collaborators

  • Actavis Inc.

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-11
Primary Completion
2015-07-23
Completion
2015-07-23

Countries

  • United States
  • Australia
  • Bulgaria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01966003 on ClinicalTrials.gov